Evidence map›Paper›PMID 29416796›Full record

ArticleOncotarget2018

CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator.

Yong Wha Moon, Hee-Jung An, Ja Seung Koo, Gun Min Kim, Hyunju Han, Seho Park, Seung Il Kim, Hyung Seok Park, Sewha Kim, Seung Ki Kim and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Yong Wha Moon *Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Hee-Jung An *Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Ja Seung KooDepartment of Pathology, Yonsei University College of Medicine, Seoul, Korea.
Gun Min KimDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Hyunju HanYonsei Cancer Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Seho ParkDepartment of Surgery, Yonsei University College of Medicine, Seoul, Korea.
Seung Il KimDepartment of Surgery, Yonsei University College of Medicine, Seoul, Korea.
Hyung Seok ParkDepartment of Surgery, Yonsei University College of Medicine, Seoul, Korea.
Sewha KimDepartment of Pathology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Seung Ki KimDepartment of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Seung Ah LeeDepartment of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Sohyun HwangDepartment of Pathology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Gun Woo SonMedical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Joohyuk SohnDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Yonsei University · KRCHA University · KRCHA University Bundang Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD44

Indexed as

breast cancerCD24estrogen-receptor positiveresistancetamoxifen

Identifiers

PMID29416796
PMCPMC5788664
OpenAlexW2777824604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.